Bristol Myers Squibb (BMY) to Release Quarterly Earnings on Thursday

Bristol Myers Squibb (NYSE:BMY) is expected to be releasing its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Bristol Myers Squibb to announce earnings of $1.60 per share and revenue of $11.7296 billion for the quarter. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Investors are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:15 AM ET.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter last year, the business earned $1.80 earnings per share. Bristol Myers Squibb’s revenue was up 2.6% on a year-over-year basis. On average, analysts expect Bristol Myers Squibb to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Bristol Myers Squibb Trading Down 0.2%

BMY opened at $60.79 on Thursday. Bristol Myers Squibb has a twelve month low of $42.52 and a twelve month high of $62.89. The company has a 50-day simple moving average of $57.29 and a 200 day simple moving average of $57.94. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The stock has a market capitalization of $124.14 billion, a price-to-earnings ratio of 17.08, a P/E/G ratio of 0.17 and a beta of 0.23.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.1%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 70.79%.

Analyst Ratings Changes

A number of brokerages have recently weighed in on BMY. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $54.00 price target on shares of Bristol Myers Squibb in a report on Monday, July 6th. Weiss Ratings cut shares of Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, July 16th. UBS Group restated a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Guggenheim restated a “buy” rating and set a $72.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Finally, Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $61.25.

Institutional Investors Weigh In On Bristol Myers Squibb

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Empire Financial Management Company LLC lifted its stake in shares of Bristol Myers Squibb by 3.3% in the fourth quarter. Empire Financial Management Company LLC now owns 6,190 shares of the biopharmaceutical company’s stock valued at $334,000 after buying an additional 200 shares in the last quarter. GW&K Investment Management LLC increased its position in shares of Bristol Myers Squibb by 16.8% during the fourth quarter. GW&K Investment Management LLC now owns 1,424 shares of the biopharmaceutical company’s stock worth $77,000 after acquiring an additional 205 shares in the last quarter. Binnacle Investments Inc raised its holdings in shares of Bristol Myers Squibb by 17.0% in the 2nd quarter. Binnacle Investments Inc now owns 1,801 shares of the biopharmaceutical company’s stock worth $83,000 after acquiring an additional 262 shares during the last quarter. Bank of Jackson Hole Trust boosted its stake in Bristol Myers Squibb by 25.5% during the 4th quarter. Bank of Jackson Hole Trust now owns 1,305 shares of the biopharmaceutical company’s stock valued at $70,000 after purchasing an additional 265 shares during the last quarter. Finally, E Fund Management Co. Ltd. boosted its stake in Bristol Myers Squibb by 2.6% during the 2nd quarter. E Fund Management Co. Ltd. now owns 10,409 shares of the biopharmaceutical company’s stock valued at $482,000 after purchasing an additional 267 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.